Wuhan Hiteck Biological Pharma Co., Ltd. (300683) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Wuhan Hiteck Biological Pharma Co., Ltd.

Why is Wuhan Hiteck Biological Pharma Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Poor long term growth as Net Sales has grown by an annual rate of 5.20% and Operating profit at -204.38% over the last 5 years

OPERATING CASH FLOW(Y) Lowest at CNY -17.61 MM
CASH AND EQV(HY) Lowest at CNY 1,627.7 MM
DEBT-EQUITY RATIO (HY) Highest at -29.92 %

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 7.08%, its profits have risen by 37.9%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Wuhan Hiteck Biological Pharma Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Wuhan Hiteck Biological Pharma Co., Ltd.

-100.0%

0.87

63.27%

China Shanghai Composite

15.19%

1.01

15.10%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

5.20%

EBIT Growth (5y)

-204.38%

EBIT to Interest (avg)

-56.97

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.30

Sales to Capital Employed (avg)

0.24

Tax Ratio

4.79%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

0.21%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.86

EV to EBIT

-27.05

EV to EBITDA

-95.37

EV to Capital Employed

2.22

EV to Sales

5.80

PEG Ratio

Dividend Yield

0.39%

ROCE (Latest)

-8.22%

ROE (Latest)

-3.73%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

NET PROFIT(9M)

At CNY -55.34 MM has Grown at 56.47%

NET SALES(HY)

At CNY 350.96 MM has Grown at 19.88%

RAW MATERIAL COST(Y)

Fallen by -44.69% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 3.45%

-7What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CNY -17.61 MM

CASH AND EQV(HY)

Lowest at CNY 1,627.7 MM

DEBT-EQUITY RATIO (HY)

Highest at -29.92 %

OPERATING PROFIT(Q)

Lowest at CNY -20.47 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -13.2 %

Here's what is working for Wuhan Hiteck Biological Pharma Co., Ltd.

Net Sales

At CNY 350.96 MM has Grown at 19.88%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Net Profit

Higher at CNY -39.85 MM

than preceding 12 month period ended Mar 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Net Profit

At CNY -39.85 MM has Grown at 62.76%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Inventory Turnover Ratio

Highest at 3.45%

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -44.69% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Wuhan Hiteck Biological Pharma Co., Ltd.

Operating Cash Flow

Lowest at CNY -17.61 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Operating Profit

Lowest at CNY -20.47 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Operating Profit Margin

Lowest at -13.2 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Cash and Eqv

Lowest at CNY 1,627.7 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -29.92 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio